Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader-Willi syndrome after GHRH plus arginine administration

A. E. Rigamonti, G. Grugni, N. Marazzi, S. Bini, M. Bidlingmaier, A. Sartorio

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Human growth hormone (GH) is a heterogeneous protein hormone consisting of several isoforms, the most abundant being 22kDa- and 20kDa-GH. The availability of analytical methods to measure these GH isoforms might represent a valuable diagnostic tool to investigate GH hyposecretory states, including Prader-Willi syndrome (PWS), one of the most common causes of syndromic obesity. The aim of the present study was to measure circulating levels of 22kDa- and 20kDa-GH in PWS adults (n=14; M/F: 5/9; genotype DEL15/UPD15: 12/2; age: 19.0±3.7years; BMI: 29.9±8.7kg/m2) after combined GH releasing hormone (GHRH) plus arginine (ARG) administration. The results were analysed subdividing the study population in obese vs. nonobese (6/8) and GH deficient vs. nonGH deficient (GHD) (6/8) subjects, according to appropriate BMI-related diagnostic cut-off limits of GH peak response to the provocative test. Circulating levels of 22kDa-GH were measured by a chemiluminescent method based on a detection monoclonal antibody targeting an epitope in the loop connecting helix 1 and 2 of GH, which is missing in 20kDa-GH; the 20kDa-GH was measured using a time resolved fluorescence assay based on two monoclonal antibodies with no cross-reactivity to 22-kDa GH.GHRH plus ARG significantly stimulated the secretions of 22. kDa- and 20. kDa-GH in nonobese (at 30, 45, 60 and 90. min and at 45, 60, 90 and 120. min vs. 0. min, p.

Original languageEnglish
Pages (from-to)168-173
Number of pages6
JournalGrowth Hormone and IGF Research
Volume25
Issue number4
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Prader-Willi Syndrome
Growth Hormone
Arginine
Protein Isoforms
Hormones
Monoclonal Antibodies
Growth Hormone-Releasing Hormone
Human Growth Hormone
Epitopes

Keywords

  • GH deficiency
  • GH isoforms
  • GHRH plus arginine
  • Obesity
  • Prader-Willi syndrome

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader-Willi syndrome after GHRH plus arginine administration. / Rigamonti, A. E.; Grugni, G.; Marazzi, N.; Bini, S.; Bidlingmaier, M.; Sartorio, A.

In: Growth Hormone and IGF Research, Vol. 25, No. 4, 01.08.2015, p. 168-173.

Research output: Contribution to journalArticle

@article{944f4b3935224fe69b3b159af163e3d4,
title = "Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader-Willi syndrome after GHRH plus arginine administration",
abstract = "Human growth hormone (GH) is a heterogeneous protein hormone consisting of several isoforms, the most abundant being 22kDa- and 20kDa-GH. The availability of analytical methods to measure these GH isoforms might represent a valuable diagnostic tool to investigate GH hyposecretory states, including Prader-Willi syndrome (PWS), one of the most common causes of syndromic obesity. The aim of the present study was to measure circulating levels of 22kDa- and 20kDa-GH in PWS adults (n=14; M/F: 5/9; genotype DEL15/UPD15: 12/2; age: 19.0±3.7years; BMI: 29.9±8.7kg/m2) after combined GH releasing hormone (GHRH) plus arginine (ARG) administration. The results were analysed subdividing the study population in obese vs. nonobese (6/8) and GH deficient vs. nonGH deficient (GHD) (6/8) subjects, according to appropriate BMI-related diagnostic cut-off limits of GH peak response to the provocative test. Circulating levels of 22kDa-GH were measured by a chemiluminescent method based on a detection monoclonal antibody targeting an epitope in the loop connecting helix 1 and 2 of GH, which is missing in 20kDa-GH; the 20kDa-GH was measured using a time resolved fluorescence assay based on two monoclonal antibodies with no cross-reactivity to 22-kDa GH.GHRH plus ARG significantly stimulated the secretions of 22. kDa- and 20. kDa-GH in nonobese (at 30, 45, 60 and 90. min and at 45, 60, 90 and 120. min vs. 0. min, p.",
keywords = "GH deficiency, GH isoforms, GHRH plus arginine, Obesity, Prader-Willi syndrome",
author = "Rigamonti, {A. E.} and G. Grugni and N. Marazzi and S. Bini and M. Bidlingmaier and A. Sartorio",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.ghir.2015.06.002",
language = "English",
volume = "25",
pages = "168--173",
journal = "Endocrinology and Metabolism, Supplement",
issn = "1096-6374",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader-Willi syndrome after GHRH plus arginine administration

AU - Rigamonti, A. E.

AU - Grugni, G.

AU - Marazzi, N.

AU - Bini, S.

AU - Bidlingmaier, M.

AU - Sartorio, A.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Human growth hormone (GH) is a heterogeneous protein hormone consisting of several isoforms, the most abundant being 22kDa- and 20kDa-GH. The availability of analytical methods to measure these GH isoforms might represent a valuable diagnostic tool to investigate GH hyposecretory states, including Prader-Willi syndrome (PWS), one of the most common causes of syndromic obesity. The aim of the present study was to measure circulating levels of 22kDa- and 20kDa-GH in PWS adults (n=14; M/F: 5/9; genotype DEL15/UPD15: 12/2; age: 19.0±3.7years; BMI: 29.9±8.7kg/m2) after combined GH releasing hormone (GHRH) plus arginine (ARG) administration. The results were analysed subdividing the study population in obese vs. nonobese (6/8) and GH deficient vs. nonGH deficient (GHD) (6/8) subjects, according to appropriate BMI-related diagnostic cut-off limits of GH peak response to the provocative test. Circulating levels of 22kDa-GH were measured by a chemiluminescent method based on a detection monoclonal antibody targeting an epitope in the loop connecting helix 1 and 2 of GH, which is missing in 20kDa-GH; the 20kDa-GH was measured using a time resolved fluorescence assay based on two monoclonal antibodies with no cross-reactivity to 22-kDa GH.GHRH plus ARG significantly stimulated the secretions of 22. kDa- and 20. kDa-GH in nonobese (at 30, 45, 60 and 90. min and at 45, 60, 90 and 120. min vs. 0. min, p.

AB - Human growth hormone (GH) is a heterogeneous protein hormone consisting of several isoforms, the most abundant being 22kDa- and 20kDa-GH. The availability of analytical methods to measure these GH isoforms might represent a valuable diagnostic tool to investigate GH hyposecretory states, including Prader-Willi syndrome (PWS), one of the most common causes of syndromic obesity. The aim of the present study was to measure circulating levels of 22kDa- and 20kDa-GH in PWS adults (n=14; M/F: 5/9; genotype DEL15/UPD15: 12/2; age: 19.0±3.7years; BMI: 29.9±8.7kg/m2) after combined GH releasing hormone (GHRH) plus arginine (ARG) administration. The results were analysed subdividing the study population in obese vs. nonobese (6/8) and GH deficient vs. nonGH deficient (GHD) (6/8) subjects, according to appropriate BMI-related diagnostic cut-off limits of GH peak response to the provocative test. Circulating levels of 22kDa-GH were measured by a chemiluminescent method based on a detection monoclonal antibody targeting an epitope in the loop connecting helix 1 and 2 of GH, which is missing in 20kDa-GH; the 20kDa-GH was measured using a time resolved fluorescence assay based on two monoclonal antibodies with no cross-reactivity to 22-kDa GH.GHRH plus ARG significantly stimulated the secretions of 22. kDa- and 20. kDa-GH in nonobese (at 30, 45, 60 and 90. min and at 45, 60, 90 and 120. min vs. 0. min, p.

KW - GH deficiency

KW - GH isoforms

KW - GHRH plus arginine

KW - Obesity

KW - Prader-Willi syndrome

UR - http://www.scopus.com/inward/record.url?scp=84937517271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937517271&partnerID=8YFLogxK

U2 - 10.1016/j.ghir.2015.06.002

DO - 10.1016/j.ghir.2015.06.002

M3 - Article

VL - 25

SP - 168

EP - 173

JO - Endocrinology and Metabolism, Supplement

JF - Endocrinology and Metabolism, Supplement

SN - 1096-6374

IS - 4

ER -